USPTO serial 79353559
KYSO ANTIBODIES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 30, 2024
- Examiner
- FLETCHER, TRACY L
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with KYSO ANTIBODIES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological preparations for use in industry and science for in vitro and in vivo scientific and industrial research and development with regard to diseases; biochemical preparations for in vitro and in vivo scientific research purposes with regard to diseases; biochemical reagents used for non-medical purposes in the nature of in vitro and in vivo scientific and industrial research with regard to diseases; chemicals for use in biotechnological product development in the nature of in vitro and in vivo industrial product development with regard to diseases; active chemical ingredients for use in the manufacture of pharmaceuticals for the treatment of cancer, autoimmune diseases, and inflammatory disorders | ACTIVE | — |
| 005 | Pharmaceutical and veterinary preparations including preparations based on antibodies, and bi- and multi-specific antibodies as well as fragments, derivatives and conjugates thereof, namely, pharmaceutical products for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, and the genitourinary system; Pharmaceutical and veterinary preparations, including preparations based on antibodies, and bi- and multi- specific antibodies as well as fragments, derivatives and conjugates thereof, for the treatment of cancer, autoimmune diseases, and inflammatory disorders | ACTIVE | — |
| 042 | Medical, scientific and biological research in the fields of antibodies, and bi- and multi-specific antibodies as well as fragments, derivatives and conjugates thereof and development of pharmaceutical products based on the same; chemical analysis; computer programming, namely, programming of computers for the collection and processing of medical data for use in medical scientific research, development and therapy and scientific research, development and therapy with antibodies and bi- and multi- specific antibodies as well as fragments, derivatives or conjugates of any of these | ACTIVE | — |
| 045 | Legal services relating to the exploitation of patents and licensing of intellectual property in the field of medicine | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Genmab A/S
- Other trademarks owned by Genmab A/S
- Other trademarks owned by Genmab A/S
- Other trademarks owned by Genmab A/S
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named KYSO ANTIBODIES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 21, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 21, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 1, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 30, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 30, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 30, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 30, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 15, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 15, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jan 15, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 15, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 14, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 14, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 13, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Oct 25, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 25, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 25, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 12, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 7, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 6, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 6, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 15, 2023 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| May 24, 2023 | RFNP | REFUSAL PROCESSED BY IB | — |
| May 4, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 3, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 15, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 14, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 13, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 1, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 28, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 27, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |